{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:44:55Z","timestamp":1791308695371,"version":"4.3.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,4,8]],"date-time":"2016-04-08T00:00:00Z","timestamp":1460073600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007458","name":"Qatar Foundation","doi-asserted-by":"publisher","award":["UREP15-019-3-008"],"award-info":[{"award-number":["UREP15-019-3-008"]}],"id":[{"id":"10.13039\/100007458","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s13318-016-0338-1","type":"journal-article","created":{"date-parts":[[2016,4,8]],"date-time":"2016-04-08T21:20:00Z","timestamp":1460150400000},"page":"221-228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Population Pharmacokinetics of Intravenous Methotrexate in Patients with Hematological Malignancies: Utilization of Routine Clinical Monitoring Parameters"],"prefix":"10.1007","volume":"42","author":[{"given":"Ahmed","family":"Nader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noran","family":"Zahran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Alshammaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Altaweel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Kassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle John","family":"Wilby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,8]]},"reference":[{"issue":"4","key":"338_CR1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMp1006304","volume":"363","author":"MA Hamburg","year":"2010","unstructured":"Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363(4):301\u20134. doi: 10.1056\/NEJMp1006304 .","journal-title":"N Engl J Med"},{"issue":"9171","key":"338_CR2","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(98)12291-2","volume":"353","author":"J Durant","year":"1999","unstructured":"Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999;353(9171):2195\u20139.","journal-title":"Lancet"},{"issue":"6","key":"338_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2165\/00003088-200140060-00002","volume":"40","author":"GE Schumacher","year":"2001","unstructured":"Schumacher GE, Barr JT. Therapeutic drug monitoring: do the improved outcomes justify the costs? Clin Pharmacokinet. 2001;40(6):405\u20139. doi: 10.2165\/00003088-200140060-00002 .","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"338_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1365-2125.2011.04054.x","volume":"73","author":"L Holmboe","year":"2012","unstructured":"Holmboe L, Andersen AM, Morkrid L, Slordal L, Hall KS. High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol. 2012;73(1):106\u201314. doi: 10.1111\/j.1365-2125.2011.04054.x .","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"338_CR5","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/j.1365-2710.2008.00966.x","volume":"33","author":"K Fukuhara","year":"2008","unstructured":"Fukuhara K, Ikawa K, Morikawa N, Kumagai K. Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data. J Clin Pharm Ther. 2008;33(6):677\u201384. doi: 10.1111\/j.1365-2710.2008.00966.x .","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"338_CR6","first-page":"403","volume":"11","author":"M Nagulu","year":"2010","unstructured":"Nagulu M, Kiran VU, Nalini Y, Reddy YN, Krishna DR. Population pharmacokinetics of methotrexate in Indian cancer patients. Asian Pac J Cancer Prev. 2010;11(2):403\u20137.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"9","key":"338_CR7","doi-asserted-by":"publisher","first-page":"e46015","DOI":"10.1371\/journal.pone.0046015","volume":"7","author":"H Ruhs","year":"2012","unstructured":"Ruhs H, Becker A, Drescher A, Panetta JC, Pui CH, Relling MV, et al. Population PK\/PD model of homocysteine concentrations after high-dose methotrexate treatment in patients with acute lymphoblastic leukemia. PLoS One. 2012;7(9):e46015. doi: 10.1371\/journal.pone.0046015 .","journal-title":"PLoS One"},{"issue":"8","key":"338_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/bdd.678","volume":"30","author":"Y Min","year":"2009","unstructured":"Min Y, Qiang F, Peng L, Zhu Z. High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy. Biopharm Drug Dispos. 2009;30(8):437\u201347. doi: 10.1002\/bdd.678 .","journal-title":"Biopharm Drug Dispos"},{"issue":"3","key":"338_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2515\/therapie\/2013031","volume":"68","author":"I Aouinti","year":"2013","unstructured":"Aouinti I, Gaies E, Trabelsi S, Salouage I, Jebabli N, Charfi R, et al. Delayed elimination of methotrexate in a patient receiving ciprofloxacin. Therapie. 2013;68(3):175\u20137. doi: 10.2515\/therapie\/2013031 .","journal-title":"Therapie."},{"issue":"2","key":"338_CR10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/106002809202600219","volume":"26","author":"ML Frenia","year":"1992","unstructured":"Frenia ML, Long KS. Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann Pharmacother. 1992;26(2):234\u20137.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"338_CR11","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1158\/1078-0432.CCR-12-2080","volume":"19","author":"E Steeg van de","year":"2013","unstructured":"van de Steeg E, van Esch A, Wagenaar E, Kenworthy KE, Schinkel AH. Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice. Clin Cancer Res. 2013;19(4):821\u201332. doi: 10.1158\/1078-0432.CCR-12-2080 .","journal-title":"Clin Cancer Res"},{"issue":"6","key":"338_CR12","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/tpj.2012.37","volume":"13","author":"N Simon","year":"2013","unstructured":"Simon N, Marsot A, Villard E, Choquet S, Khe HX, Zahr N, et al. Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy. Pharmacogenomics J. 2013;13(6):507\u201313. doi: 10.1038\/tpj.2012.37 .","journal-title":"Pharmacogenomics J."},{"key":"338_CR13","unstructured":"Beal S, Sheiner L, Boeckmann A, et al. NONMEM User\u2019s Guide. Ellicott City: Icon Development Solutions; 1989\u20132009."},{"issue":"1","key":"338_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1365-2125.2005.02513.x","volume":"62","author":"M Joerger","year":"2006","unstructured":"Joerger M, Huitema AD, van den Bongard HJ, Baas P, Schornagel JH, Schellens JH, et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol. 2006;62(1):71\u201380. doi: 10.1111\/j.1365-2125.2005.02513.x .","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"338_CR15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/CAD.0b013e3282f21376","volume":"19","author":"C Dupuis","year":"2008","unstructured":"Dupuis C, Mercier C, Yang C, Monjanel-Mouterde S, Ciccolini J, Fanciullino R, et al. High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy. Anticancer Drugs. 2008;19(3):267\u201373.","journal-title":"Anticancer Drugs"},{"issue":"6","key":"338_CR16","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/FTD.0b013e31823615e1","volume":"33","author":"AM Johansson","year":"2011","unstructured":"Johansson AM, Hill N, Perisoglou M, Whelan J, Karlsson MO, Standing JF. A population pharmacokinetic\/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma. Ther Drug Monit. 2011;33(6):711\u20138. doi: 10.1097\/FTD.0b013e31823615e1 .","journal-title":"Ther Drug Monit"},{"key":"338_CR17","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2014_011","author":"J Mao","year":"2013","unstructured":"Mao J, Zhang L, Shen H, Tang Y, Song H, Zhao F, et al. Creatinine clearance rate and serum creatinine concentration are related to delayed methotrexate elimination in children with lymphoblastic malignancies. Neoplasma. 2013;. doi: 10.4149\/neo_2014_011 .","journal-title":"Neoplasma."},{"issue":"12","key":"338_CR18","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s40262-014-0179-5","volume":"53","author":"S Pan","year":"2014","unstructured":"Pan S, Stamp LK, Duffull SB, Barclay ML, Dalrymple JM, Drake J, et al. Assessment of the relationship between methotrexate polyglutamates in red blood cells and clinical response in patients commencing methotrexate for rheumatoid arthritis. Clin Pharmacokinet. 2014;53(12):1161\u201370. doi: 10.1007\/s40262-014-0179-5 .","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"338_CR19","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/j.transproceed.2004.04.097","volume":"36","author":"T Minematsu","year":"2004","unstructured":"Minematsu T, Sugiyama E, Kusama M, Hori S, Yamada Y, Ohtani H, et al. Effect of hematocrit on pharmacokinetics of tacrolimus in adult living donor liver transplant recipients. Transplant Proc. 2004;36(5):1506\u201311. doi: 10.1016\/j.transproceed.2004.04.097 .","journal-title":"Transplant Proc."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-016-0338-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-016-0338-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-016-0338-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-016-0338-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T11:44:40Z","timestamp":1559475880000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-016-0338-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,8]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["338"],"URL":"https:\/\/doi.org\/10.1007\/s13318-016-0338-1","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,8]]}}}